Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05605678 |
|
Recruitment Status :
Recruiting
First Posted : November 4, 2022
Last Update Posted : November 2, 2023
|
Sponsor:
ApcinteX Ltd
Collaborator:
Centessa Pharmaceuticals plc
Information provided by (Responsible Party):
ApcinteX Ltd
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of this study is to obtain prospective baseline documentation of annualized bleeding rates (ABRs) and treatment under standard-of-care (SOC) therapy among participants with hemophilia A or B. Participants in the study may be eligible to enroll in future planned interventional studies to be conducted by Sponsor.
| Condition or disease | Intervention/treatment |
|---|---|
| Hemophilia A Hemophilia B | Other: No Intervention |
| Study Type : | Observational |
| Estimated Enrollment : | 200 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | A Global, Non-interventional Study to Prospectively Evaluate Bleeding Episodes and Treatment Use in Patients With Hemophilia |
| Actual Study Start Date : | December 9, 2022 |
| Estimated Primary Completion Date : | November 2024 |
| Estimated Study Completion Date : | November 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Hemophilia
| Group/Cohort | Intervention/treatment |
|---|---|
|
All Eligible Participants
All Participants diagnosed with severe HemA with or without inhibitors, moderately severe to severe HemB, or HemB with inhibitors will be enrolled and continue to receive their usual hemophilia treatment regimen under SOC therapy. Bleeding episodes and treatment data will be collected during the prospective follow up period in a diary. No intervention will be administered as part of this study.
|
Other: No Intervention
This is a non-interventional study. |
Primary Outcome Measures :
- Annualized Bleeding Rate (ABR) for Treated Bleeds and All Bleeds [ Time Frame: Minimum 12 weeks ]ABR for treated bleeds and all bleeds at the participant and bleed level (excluding bleeding episodes during surgery and/or procedures).
- Average Dose (IU/kg) of Associated Treatment Received for Bleeding Episodes per Hemophilia Product per Time Period and per Bleeding Episode [ Time Frame: Minimum 12 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 65 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Participants with severe HemA with or without inhibitors, or moderately severe to severe HemB without inhibitors or HemB with inhibitors treated with SOC on-demand or prophylactic hemophilia therapy.
Criteria
Inclusion Criteria:
- Male participants greater than or equal to (>=) 12 and less than or equal to (<=) 65 years of age
- Who are capable of providing written informed consent (adolescent assent and parental/guardian consent when appropriate) for participation after reading the information and consent form and having the opportunity to discuss the study with the Investigator or their designee
- With historically documented severe HemA (defined as factor VIII [FVIII] less than (<) 0.01 International Units per milliliter (IU/mL) [<1 percent {%}]), with or without inhibitors, or moderately severe to severe HemB (defined as factor IX [FIX] <=0.02 IU/mL [<=2%]) without inhibitors. Participants must be currently included in a prophylactic treatment program or if undergoing an on-demand treatment regimen must have had >=6 documented acute bleeding episodes (spontaneous or traumatic) that required coagulation factor infusion during the 6 months before enrollment OR: Historically documented HemB (defined as FIX <=0.05 IU/mL [<=5%]) with inhibitors with a historical or ongoing high titer inhibitor [>=5 Bethesda Units/mL] based on medical records or laboratory reports) and an ABR of >=6 in the 6 months before enrollment
- Who are able to use a diary to document bleeding events and associated treatment
Exclusion Criteria:
- With known thrombophilia
- With body weight greater than (>)150 kilogram (kg) or body mass index >40
- With known current inadequate hematologic function (eg, platelet count <100,000 per microliter [/mcL] and/or hemoglobin level <10 grams per deciliter [g/dL], <100 g/L), hepatic function (that is, total bilirubin >1.5*upper limit of normal [ULN] [excluding Gilbert syndrome], aspartate transferase and/or alanine aminotransferase levels >3*ULN; clinical signs or known laboratory or radiographic evidence consistent with cirrhosis of the liver) or renal function (that is, serum creatinine >2*ULN; based on medical records or available laboratory reports)
- With previous deep vein thrombosis and pulmonary embolism, myocardial infarction, or stroke
- With history of intolerance to subcutaneous injections
- With known current uncontrolled hypertension (systolic blood pressure >160 millimeter of mercury (mm Hg); diastolic blood pressure >100 mm Hg; based on medical records)
- With active cancer or requires therapy for cancer, except for basal cell carcinoma
- With concurrent participation in an interventional clinical trial
- With current or planned use of emicizumab
- With prior, ongoing, or planned treatment with gene therapy for hemophilia
- With history of or other evidence of recent alcohol or drug abuse as determined by the Investigator or their designee (in the 12 months before enrollment)
- With known Human Immunodeficiency Virus (HIV) infection with CD4 count (or T-cell count) of <200 cells/mcL within 24 weeks before enrollment
- With current or planned treatment with anticoagulant or antiplatelet drugs
- With any other significant conditions or comorbidities that, in the opinion of the Investigator or their designee, would make the participant unsuitable for enrollment
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05605678
Contacts
| Contact: Centessa Pharmaceuticals | 617 468 5770 | presentprogram@centessa.com |
Locations
Show 58 study locations
Sponsors and Collaborators
ApcinteX Ltd
Centessa Pharmaceuticals plc
| Responsible Party: | ApcinteX Ltd |
| ClinicalTrials.gov Identifier: | NCT05605678 |
| Other Study ID Numbers: |
AP-0105 (PRESent-5) |
| First Posted: | November 4, 2022 Key Record Dates |
| Last Update Posted: | November 2, 2023 |
| Last Verified: | November 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Keywords provided by ApcinteX Ltd:
|
Hemophilia Prospective |
Additional relevant MeSH terms:
|
Hemophilia A Hemophilia B Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases |
Coagulation Protein Disorders Hemorrhagic Disorders Genetic Diseases, Inborn Genetic Diseases, X-Linked |